Quick Answer
Beta Bionics, Inc. reported Cash and Equivalents of $31.58 million for fiscal year 2025.
Beta Bionics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $31.58M | +3.8% |
| 2024 | $30.43M | +14.6% |
| 2023 | $26.57M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $38.48M | +120.2% | +9.7% |
| June 30, 2025 | $35.08M | +169.2% | -17.4% |
| March 31, 2025 | $42.45M | +92.3% | +39.5% |
| December 31, 2024 | $30.43M | — | +74.1% |
| September 30, 2024 | $17.48M | — | +34.2% |
| June 30, 2024 | $13.03M | — | -41.0% |
| March 31, 2024 | $22.07M | — | — |
- Beta Bionics, Inc. showed an increase of +3.8% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2023–2025 period, Beta Bionics, Inc.’s cash and equivalents has grown by 18.9% (from $26.57 million to $31.58 million).
- The most recent figure is from Beta Bionics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: